ПЛАЗМИД-ИНДУЦИРОВАННАЯ РЕЗИСТЕНТНОСТЬ ВОЗБУДИТЕЛЕЙ ИНФЕКЦИЙ МОЧЕВОЙ СИСТЕМЫ
Анотація
В представленном обзоре рассмотрены механизмы формирования резистентности к антибактериальной терапии, индуцированные плазмидами и связанные с выработкой генов устойчивости.
Завантаження
Посилання
Колесник М.О. Адаптована клінічна настанова з кращої практики діагностики, лікування та профілактики інфекцій сечової системи у жінок / М.О. Колесник, Н.М. Степанова, Л.О. Лебідь, [та ін.] // Український журнал нефрології та діалізу. - 2012. - №2 (34). - С. 53-77.
Колесник М.О. Медико-профілактична допомога хворим нефрологічного профілю в Україні / М.О. Колесник, Н.О. Сайдакова, Н.І. Козлюк «та ін.» // Український журнал нефрології та діалізу. - 2011. - №4(32). - С. 3-11.
Колесник М.О. Національний реєстр хворих на хронічну хворобу нирок 2010 / М.О. Колесник, Н.І. Козлюк, Г.С. Владзієвська, М.В. Кулизький // Державна установа «Інститут нефрології АМН України». - Київ. - 2011. - С. 10-22.
Boucher HW. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society ofAmerica / Boucher HW, Talbot GH, Bradley JS // Clin Infect Dis. - 2009. - №48. - P.1-12.
Carattoli A. Plasmids and the spread of resistance / A. Carattoli // Int J Med Microbiol. – 2013. – № 303(6-7). - P. 298-304.
Chong Y. Genetic evolution and clinical impact in extended-spectrum P-lactamase-producing Escherichia coli and Klebsiella pneumonia / Chong Y, Ito Y, Kamimura T // Infect Genet Evol. - 2011. - № 11(7). - P.1499-1504.
Curcio D. Multidrug-Resistant Gram-Negative Bacterial Infections: Are you Ready for the Challenge? / D.Curcio // Curr Clin Pharmacol. - 2013. - № 12. [Epub ahead of print].
Dalhoff A. Global Fluoroquinolone Resistance Epidemiology and Implictions for Clinical Use / A. Dalhoff // Interdisciplinary Perspectives on Infectious Diseases. - 2012. - № ID 976273. - P. 1-37.
D’Andrea MM. CTX-M-type P-lactamases: a successful story of antibiotic resistance / D’Andrea MM, Arena F, Pallecchi L [et al.] // Int J Med Microbiol. - 2013. - № 303(6-7). - P. 305-317.
Datta P. Epidemiology of Extended-Spectrum P-Lactamase, AmpC, and Carbapenemase Production in Proteus mirabilis / Datta P, Gupta V, Arora S [et al.] // Jpn J Infect Dis. - 2014. - № 67(1). - P. 44-46.
Denys GA. Antimicrobial susceptibility among gramnegative isolates collected in the USA between 2005 and 2011 as part of the Tigecycline Evaluation and Surveillance Trial (T.E.S.T.) / Denys GA, Callister SM, Dowzicky MJ // Ann Clin Microbiol Antimicrob. - 2013. - № 5. - P. 12-24.
Endimiani A. Bacteremia due to Klebsiella pneumoniae isolates producing the TEM-52 extended-spectrum P-lactamase: treatment outcome of patients receiving imipenem or ciprofloxacin / Endimiani A, Luzzaro F, Perilli M [et al.] // Clin Infect Dis. - 2004. - №38. - P. 243-251.
Gardiner BJ. Is fosfomycin a potential treatment alternative for multidrug-resistant gram-negative prostatitis? / Gardiner BJ, Mahony AA, Ellis AG[et al.] // Clin Infect Dis. - 2014. - № 58(4). - P. 101-105.
Gibold L. Four-year epidemiological study of extended-spectrum P-lactamase-producing Enterobacteriaceae in a French teach ing hospital / Gibold L, Robin F, Tan RN [et al.] // Clin Microbiol Infect. - 2014. - № 20(1). - P. 20-26.
Gupta K. Management of Urinary Tract Infections From Multidrug-Resistant Organisms / Gupta K, Bhadelia N // Infect Dis Clin North Am. - 2014. - № 28(1). - P. 49-59.
Huh K. Continuous increase of the antimicrobial resistance among gram-negative pathogens causing bacteremia: a nationwide surveillance study by the Korean Network for Study on Infectious Diseases (KONSID) / Huh K, Kim J, Cho SY [et al.] // Diagn Microbiol Infect Dis. - 2013. - № 76(4). - P. 477-482.
Kanj SS. Current concepts in antimicrobial therapy against resistant gram-negative organisms: extended-spectrum beta-lactamase-pro ducing Enterobacteriaceae, carbapenem-resis- tant Enterobacteriaceae, and multidrug-resistant Pseudomonas aeruginosa / Kanj SS, Kanafani ZA // Mayo Clin Proc. - 2011.- № 86(3). - P 250-259.
Kruse EB. Carbapenem-Resistant Enterobacteriaceae: Laboratory Detection and Infection Control Practices / Kruse EB, Aurbach U, Wisplinghoff H // Curr Infect Dis Rep. – 2013. – № 12. [Epub ahead of print].
Lee J. The impact of the increased use of piperacil- lin/tazobactam on the selection of antibiotic resistance among invasive Escherichia coli and Klebsiella pneumoniae isolates / Lee J, Oh CE, Choi EH // Int J Infect Dis. – 2013.- № 17(8). – P. 638-643.
Li W. Increasing Occurrence ofAntimicrobial-Resistant Hypervirulent (Hypermucoviscous) Klebsiella pneumoniae Isolates in China / Li W, Sun G, Yu Y [et al.] // Clin Infect Dis. – 2014. – № 58(2). – P. 225-232.
Lim CL. Evaluation of Ertapenem use with impact assessment on extended-spectrum beta-lactamases (ESBL) production and gram-negative resistance in Singapore General Hospital (SGH) / Lim CL, Lee W, Lee AL [et al.] // BMC Infect Dis. – 2013. – № 6. – P. 513-523.
Lopez-Cerero L. Comparative assessment of inoculum effects on the antimicrobial activity of amoxy- cillin-clavulanate and piperacillin-tazobactam with extended-spectrum beta-lactamase-producing and extended-spectrum beta-lactamase-non-producing Escherichia coli isolates / Löpez-Cerero L, Picon E, Morillo C [et al.] // Clin Microbiol Infect. – 2010. – № 16(2). – P. 132-136.
Macvane SH. Prolonging P-lactam infusion: A review of the rationale and evidence, and guidance for implementation / Macvane SH, Kuti JL, Nicolau DP // Int J Antimicrob Agents. – 2014. – № 43(2). – P.105-113.
Munoz-Price LS. Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapen- emases / Munoz-Price LS, Poirel L, Bonomo RA [et al.] // Lancet Infect Dis. – 2013. – № 13(9). – P. 785-796.
Page MG. Extended-spectrum P-lactamases: structure and kinetic mechanism / Page MG // Clin Microbiol Infect. – 2008. – № 14 (suppl 1). – P. 63-74.
Peterson LR. Antibiotic policy and prescribing strategies for therapy of extended-spectrum P-lactamase- producing Enterobacteriaceae: the role of pipera- cillin-tazobactam / Peterson LR // Clin Microbiol Infect. – 2008. – № 14 (suppl 1). – P. 181-184.
Pitout JD. Extended-spectrum P-lactamase- producing Enterobacteriaceae: an emerging public- health concern / Pitout JD, Laupland KB // Lancet Infect Dis. – 2008. – №8. – P. 159-166.
Pitout JD. Extraintestinal pathogenic Escherichia coli: an update on antimicrobial resistance, laboratory diagnosis and treatment / Pitout J // Expert Rev Anti Infect Ther. – 2012. – № 10(10). – P. 1165-1176.
Poirel L. Plasmid-mediated quinolone-resistance; interactions between human, animal and environmental ecologies / L. Poirel, V. Cattoir, P. Nordmann // Frontiers in Microbiology. - 2012. - №3(24). - P. 1-7.
Pontikis K. Outcomes of critically ill intensive care unit patients treated with fosfomycin for infections due to pandrug-resistant and extensively drug-resistant carbapenemase-producing Gram-negative bacteria / Pontikis K, Karaiskos I, Bastani S [et al.] // Int J Antimicrob Agents. - 2014. - № 43(1). - P. 52-59.
Rodriguez-Bano J. Community infections caused by extended-spectrum P-lactamase-producing Escherichia coli / Rodriguez-Bano J, Alcala JC, Cisneros JM [et al.] // Arch Intern Med. - 2008.- №168. - P.1897-1902.
Sanchez GV. In vitro antimicrobial resistance of urinary E. coli among U.S. outpatients from 2000 to 2010 / G.V. Sanchez, R.N. Master, J.A. Karlowsky // Antimicrob Agents Chemother. - 2012. - №56. - P. 2181-2183.
Schito G. C. The ARESC study: an international survey on the antimicrobial resistance of pathogens involved in uncomplicated urinary tract infections / G. C. Schito, K. G. Naber, H. Botto [et al.] // International Journal of Antimicrobial Agents. - 2009. - №5. - P. 407-413.
Schwaber MJ. An Ongoing National Intervention to Contain the Spread of Carbapenem-Resistant Enterobacteriaceae / Schwaber MJ, Carmeli Y // Clin Infect Dis. - 2014.- № 6. - P. 123-125.
Tan TY. CTX-M and AmpC Beta-lactamases Contributing to Increased Prevalence of Ceftriaxone-resistant Escherichia coli in Changi General Hospital, Singapore / Tan TY, Ng LS, He J [et al.] // Diagn Microbiol Infect Dis. – 2010. – №13(2). – Р. 210-213.
Tzouvelekis L.S. Carbapenemases in Klebsiella pneumoniae and Other Enterobacteriaceae: an Evolving Crisis of Global Dimensions / Tzouvelekis L.S., Markogiannakis A., Psichogiou M. // Clin Microbiol Rev. - 2012. - №25(4). - Р. 682-707.
Valenza G. Extended-Spectrum-ß-Lactamase- Producing Escherichia coli as Intestinal Colonizers in the German Community / Valenza G, Nickel S, Pfeifer Y // Antimicrob Agents Chemother. – 2014. – № 58(2). - Р. 1228-1230.
Veldman K. International collaborative study on the occurrence of plasmid-mediated quinolone resistance in Salmonella enterica and Escherichia coli isolated from animals, humans, food and the environment in 13 European countries / Veldman K, Cavaco LM, Mevius D [et al.] // J Antimicrob Chemother. - 2011.- № 66(6). - Р. 1278-1286.
Wailan AM. The spread and acquisition of NDM-1: a multifactorial problem / Wailan AM, Paterson DL // Expert Rev Anti Infect Ther. - 2014. - № 12(1). - Р. 91-115.
Wolska K. Resistance of Pseudomonas aeruginosa to antibiotics / Wolska K, Kot B, Piechota M [et al.] // Postepy Hig Med Dosw (Online). - 2013. - №16. - Р. 1300-1311.
Журнал розповсюджується за ліцензією 